These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18386291)

  • 1. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
    Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
    Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Bologna M
    Prostate; 2008 Jun; 68(9):965-74. PubMed ID: 18361408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
    Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
    Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB; Solit D; Basso A; Moasser MM
    Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
    Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
    Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
    Lee YY; Kim HP; Kang MJ; Cho BK; Han SW; Kim TY; Yi EC
    Exp Mol Med; 2013 Nov; 45(11):e64. PubMed ID: 24263233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.
    El Sheikh SS; Domin J; Abel P; Stamp G; Lalani el-N
    Neoplasia; 2004; 6(6):846-53. PubMed ID: 15720812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
    Li P; Torossian A; Zhang Q; Xu WC; Fu S
    Med Oncol; 2012 Dec; 29(5):3258-64. PubMed ID: 22729368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.